ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1339

Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)

Matthew Wong-Pack1, Elliot Hepworth2, Mohammad Movahedi3, Bindee Kuriya1, Janet Pope4, Edward Keystone5, Carter Thorne6, VANDANA AHLUWALIA7, Angela Cesta8, Carol Mously8, Claire Bombardier1, Arthur Lau9 and Sibel Aydin10, 1University of Toronto, Toronto, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4University of Western Ontario, London, ON, Canada, 5Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 6Southlake Regional Health Centre, Newmarket, ON, Canada, 7William Osler Health System, Brampton, ON, Canada, 8University Health Network, Toronto, ON, Canada, 9McMaster University, Hamilton, ON, Canada, 10University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada

Meeting: ACR Convergence 2022

Keywords: COVID-19, Disease Activity, Disease-Modifying Antirheumatic Drugs (Dmards), Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in physical activity, and management of disease activity. Our study examined the impact of the pandemic on RA patients reported outcomes (PROs), disease activity (DA) and medication profiles before and after the pandemic.

Methods: The Ontario Best Practices Research Initiative (OBRI) is an observational cohort of adult patients with active RA. We defined two study periods of one year duration each: (1) a pre-COVID-19 pandemic phase (12 months before March 15th, 2020) and (2) a COVID-19 pandemic phase (12 months after March 15th 2020). Patients enrolled in OBRI were included in the analysis if they had at least one visit with a physician or interviewer (virtually) in both study periods. Baseline characteristics, disease activity (DA), as well as other PROs (i.e. Health Assessment Questionnaire Disability Index, Rheumatoid Arthritis Disease Activity Index, EuroQoL- 5 Dimension Questionnaire, and medication use / changes) were included. Paired two-sample t-test and McNamar’s test was performed for continuous and categorical variables, respectively.

Results: We identified 1508 patients (mean age = 62.7, 79.3% female). Tables 1 and 2 outline changes in disease activity measures and PROs, respectively. During the first year of the pandemic, the number of physician visits per patient increased by a mean of 0.21 visits (SD:1.51) (p < 0.0001). Despite the patient global and physician global assessments and composite DA scores being similar before and after the pandemic, swollen joint count (SJC) and tender joint counts (TJC) showed improvement during the pandemic (differences of -0.49 (3.04), p < 0.0001 and -0.40 (3.73), p < 0.003 respectively). Similar improvements were observed in PROs, such as RADAI (-0.17 (1.40), p = 0.002) and fatigue (-0.48 (2.42), p < 0.0001). There were also statistically significant changes in treatment during the pandemic with decreased biologic (32.6% vs 29.9%; p=0.002) and conventional synthetic DMARDs use (83.3% vs 79.5%; p< 0.0001), while prescription of targeted synthetic DMARDs increased during the pandemic (12.1% vs 15.4%; p< 0.0001).

Conclusion: Disease activity and treatments for RA changed during the pandemic. Improvements in PROs may be explained by changes in patients’ lifestyle, such as being able to work from home. Changes in medication profiles may relate to preference of oral agents or those with shorter half-life given the concern of immunosuppression. Future work is needed to determine if these changes persist and what implications they may have beyond the pandemic.

Supporting image 1

Supporting image 2


Disclosures: M. Wong-Pack, None; E. Hepworth, None; M. Movahedi, None; B. Kuriya, None; J. Pope, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Eli Lilly, merk, Roche, Seattle Genetics, UCB, Actelion, Amgen, Bayer, Eicos Sciences, Emerald, Gilead, Janssen, Novartis, Pfizer, Sandoz, Sanofi, Boehringer Ingelheim; E. Keystone, AbbVie/Abbott, Amgen, Gilead, Eli Lilly, Merck/MSD, Pfizer, Sanofi, Bristol-Myers Squibb(BMS), Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Genentech, Janssen, Sandoz, Samsung Bioepsis, AstraZeneca, Samsung Bioepsis; C. Thorne, AbbVie/Abbott, Amgen, Celgene, CaREBiodam, Centocor, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Medexus/Medac, Merck; V. AHLUWALIA, None; A. Cesta, None; C. Mously, None; C. Bombardier, Amgen, AbbVie, Gilead, Janssen, Eli Lilly, Merck/MSD, Medexus, Medreleaf/Aurora, Novartis, Pfizer, Roche, Sandoz, Sanofi/Genzyme, Samsung, Mylan, GlaxoSmithKlein(GSK); A. Lau, AbbVie/Abbott, Amgen, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Merck/MSD, Novartis, Janssen, Pfizer, Roche, Sanofi, UCB; S. Aydin, None.

To cite this abstract in AMA style:

Wong-Pack M, Hepworth E, Movahedi M, Kuriya B, Pope J, Keystone E, Thorne C, AHLUWALIA V, Cesta A, Mously C, Bombardier C, Lau A, Aydin S. Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/impact-of-the-covid-19-pandemic-on-patients-with-rheumatoid-arthritis-data-from-the-ontario-best-practices-research-initiative-obri/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-the-covid-19-pandemic-on-patients-with-rheumatoid-arthritis-data-from-the-ontario-best-practices-research-initiative-obri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology